Intalight™ Receives CE Mark for Its Progressive DREAM OCT™ Swept Source Imaging
SAN JOSE, Calif. and SHANGHAI, May 15, 2025 /CNW/ -- Intalight™, a company that develops advanced ophthalmic technologies and a leader in Optical Coherence Tomography (OCT) today announced it has received CE mark for its DREAM OCT™ platform.
The CE mark serves as approval by the European Union (EU) to commercialize DREAM OCT, the newest version of OCT. DREAM stands for: Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate results, and Multimodal imaging capabilities. The imaging platform provides the highest quality OCT images currently on the market.
"Intalight is incredibly proud to receive CE mark approval in Europe for our DREAM OCT," said Intalight chairman and Founder, Shawn Peng. "This achievement allows us to provide ophthalmologists in Europe with state-of-the-art technology that delivers improved results for their patients."
DREAM OCT is able to cover an ultrawide field single scan which delivers a 130° OCTA image. DREAM OCT™ swept-source 12 mm super-depth scanning allows superior imaging of the choroid and retina, and a large portion of the vitreous space. The super-depth anterior scanning capabilities achieves 16.2 mm (in air), allowing for the complete anterior segment from the cornea to the anterior part of the vitreous to be scanned in only one scan. The longer wavelength allows for superior penetration through opacities in either lens or vitreous.
"Over the past few years, we've heard from eye care professionals that they need a solution that gets them over the imaging finish line with speed, accuracy and depth," said Intalight CEO and Co-Founder, Bing Li. "DREAM OCT delivers a full set of imaging modalities for the most challenging clinical and research applications for the retina and outperforms everything else HCP's know."
Using ultra-wide swept-source technology, DREAM OCT was developed to address the needs of retina specialists, comprehensive ophthalmologists and their patients with highly-detailed imaging capabilities for improved care and results. Currently, more than 160 peer-reviewed papers have utilized findings from DREAM OCT devices.
"This is such exciting news for Intalight that there's no more waiting in Europe, and we look forward to being able to provide this innovative solution in the US," remarked Intalight Chief Commercial Officer, Joe Garibaldi. "We look forward to continuing to grow our prestigious network of global institutions and ophthalmologists with our recent CE approval and eventually our FDA approval."
As the clinically validated leader of ultra-wide field OCTA, Intalight is currently collaborating with the top retina academic institutions and retina private practices in the United States, Europe, and Asia.
About Intalight
Intalight Inc. was founded by a group of scientists and industry veterans of Silicon Valley with a core mission to develop the most advanced ophthalmic technologies. There are now three sites in Silicon Valley, Shanghai, and Luoyang. Intalight's Swept-Source Optical Coherence Tomography (OCT) device combines Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate lesion detection and Multimodal imaging capabilities, and is abbreviated as DREAM OCT™. The powerful imaging device has become an indispensable tool for many ophthalmologists in not only their daily clinical use but also their exploration of the research frontiers. To learn more about Intalight and DREAM OCT, please visit our website at https://www.intalight.com and follow us on LinkedIn and Facebook.
View original content to download multimedia:https://www.prnewswire.com/news-releases/intalight-receives-ce-mark-for-its-progressive-dream-oct-swept-source-imaging-302454390.html
SOURCE Intalight Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2025/15/c3929.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
a day ago
- Hamilton Spectator
Jetoptera Executes FETT for FTC-250 at Paris Air Show 2025
PARIS, June 21, 2025 (GLOBE NEWSWIRE) — On the occasion of Jetoptera's debut at the Paris Air Show 2025, we are proud to announce the successful completion of the first test of the engine that will power the J-500, the 500-lb VTOL cargo unmanned aircraft system Jetoptera is developing in collaboration with Eanan Al Samma, for the United Arab Emirates (UAE) market. The First Engine To Test (FETT) was evaluated at the VAN DER LEE Turbo Systems facilities in Zaandam, The Netherlands. The 250 kW turbocompressor, that is the heart of the Fluidic Propulsive System™, is a two-shaft engine using a free turbine that is mechanically coupled to a two-stage axial compressor designed to produce the appropriate flow rates and pressure ratios required by the FPS™. 'The FETT demonstrated a very smooth startup and operability when operated in a turbofan mode. The engine was instrumented in this configuration, to monitor pressure and temperature as well as thrust produced. The next step includes the performance mapping of the turbocompressor, followed by the integration with the FPS™ onto the J-500 airframe,' said Dr Andrei Evulet, CEO/CTO of Jetoptera, Inc. The J-500 prototype is developed specifically for the UAE and MENA market and will be uniquely enabled by the FPS™ to perform unmanned cargo missions with VTOL and unmatched speed, low noise, and reliability thanks to the patented propulsion system. The modularity of the FTC-250 system allows its components to operate in turbojet, turbofan and FPS™ modes. Jetoptera and Eanan Al Samma thank Parametric Solutions, Inc. and VAN DER LEE Turbo Systems for their critical support in the design and manufacturing of the unique FTC-250 architecture in record time. For information about this press release please contact Todd Newton todd@ Jetoptera, Inc. Facebook: LinkedIn: A photo accompanying this announcement is available at
Time Business News
a day ago
- Time Business News
How to Choose the Best Solar Inverter for Home (2025)
A best solar inverter for home is the backbone of any residential solar power system. It converts the direct current (DC) from your solar panels into alternating current (AC) used by home appliances. But not all inverters are created equal—some are optimized for smaller loads, while others offer advanced features like battery compatibility and smart monitoring. The types of best solar inverter for home helps narrow down the best choice for your home setup. The most common type for homes, string inverters are cost-effective and work well when panels are evenly exposed to sunlight. Ideal for average-sized homes. These are installed on each individual panel and work best when your panels face different directions or are partially shaded. They increase energy yield and allow panel-level monitoring. These inverters allow connection to both solar panels and batteries. If you're planning for energy storage or using a grid-tied system with backup power, this is an ideal choice. If your home uses sensitive electronics like refrigerators, air conditioners, or medical devices, a pure sine wave inverter for appliances ensures stable and clean power delivery. It mimics the smooth waveform of electricity from the grid, reducing wear and tear on appliances. For compact homes or cabins, a low watt inverter for small homes is sufficient. These are often lightweight, affordable, and tailored for running essentials like fans, lights, and TVs. Choosing a smaller-capacity inverter helps save on initial investment and electricity wastage. The 2025 market offers numerous budget home inverter models that balance price and performance. These inverters may not have advanced features like Wi-Fi monitoring or battery compatibility but are perfect for straightforward solar systems with limited loads. A truly energy efficient inverter for home can have conversion efficiencies above 95%, meaning less energy is lost during DC to AC conversion. Look for inverters with certifications like IEC, UL, or CE that ensure high performance and safety standards. Wi-Fi or Bluetooth Monitoring : Lets you track energy generation and system health via mobile apps. : Lets you track energy generation and system health via mobile apps. Battery Compatibility : Useful if you want to store solar energy for nighttime use or power outages. : Useful if you want to store solar energy for nighttime use or power outages. Weatherproofing : Important for inverters installed outdoors. : Important for inverters installed outdoors. Surge Capacity: Ensure the inverter can handle sudden spikes in demand from heavy-load appliances. Proper use and installation of your inverter can maximize its benefits: Correct Sizing: Don't oversize or undersize. Oversized inverters waste money; undersized ones can overheat or fail. Professional Installation: Always hire certified technicians to install your inverter for safety and optimal functioning. Routine Maintenance: Dust, moisture, and wiring issues can degrade performance. Regular checks help maintain efficiency. Ventilation: Keep the inverter in a cool, shaded, and well-ventilated area to prevent overheating. Brand Model Best For Notable Feature Victron Energy Phoenix Inverter Sensitive Appliances Pure sine wave Growatt SPF 3000TL HVM Budget Homes Hybrid & battery-ready Renogy 1000W Inverter Small Homes Lightweight and compact Fronius Primo GEN24 Efficiency Seekers Smart tech & high efficiency Luminous Zelio+ 1100 General Use Good local support in South Asia Compare brands with a local presence to reduce maintenance and warranty issues. Look for older models from premium brands—they often get price cuts without a huge performance gap. Avoid no-name brands with unclear specifications or no customer support. Consider inverter-battery combo deals for extra savings. Q1: Can I run an AC on a solar inverter? Yes, but ensure it's a pure sine wave inverter with adequate surge capacity. Q2: How long do solar inverters last? Typically 10–15 years, though premium models can last longer with proper maintenance. Q3: What's the difference between a solar inverter and a normal inverter? A solar inverter is designed to work with solar panels, converting solar DC to usable AC. A normal inverter simply stores and converts battery power without solar input. Investing in the best solar inverter for home in 2025 means more than just picking a device—it's about ensuring energy efficiency, reliability, and future-proofing your solar setup. Whether you're in need of a low watt inverter for small homes, a pure sine wave inverter for appliances, or a budget home inverter 2025, understanding your needs and system compatibility is crucial. Make the smart choice now, and enjoy cleaner, greener energy for years to come. Buy Now at TIME BUSINESS NEWS
Yahoo
2 days ago
- Yahoo
Innocan Pharma Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference
HERZLIYA, Israel and CALGARY, AB, June 20, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces that the recently published narrative review titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" (DOI: has been officially accepted for presentation at PAINWEEK 2025, the national conference on pain management, taking place this September in Las Vegas, Nevada. PAINWEEK is a prestigious event that brings together leading clinicians, researchers, and educators in the field of pain medicine, offering a unique platform to showcase innovative research and best practices. The narrative review, selected through a competitive peer-review process, provides important insights into the potential of synthetic cannabidiol (CBD), administered through extended-release formulations, as a well-tolerated, non-opioid analgesic alternative. Innocan is developing LPT-CBD, an innovative injectable liposomal drug product designed for the sustained release of synthetic CBD. Supported by multiple animal studies, LPT-CBD has demonstrated steady plasma CBD levels for up to four weeks, prolonged pain relief, and excellent tolerability—offering a promising alternative to current opioid medications and addressing the urgent need to reduce opioid dependency. LPT-CBD will be showcased at the PAINWEEK conference to thousands of healthcare professionals and potential pharmaceutical partners, positioning it at the forefront of groundbreaking non-opioid chronic pain management solutions. "We are honored to be included among the esteemed voices presenting at PAINWEEK this year," said Iris Bincovich, Chief Executive Officer of Innocan. "This recognition underscores our commitment to advancing evidence-based pain care and contributing meaningful research to the field." About Innocan: Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales. Contact Information: For Innocan Pharma Corporation:Iris Bincovich, CEO+1 5162104025+972-54-3012842+442037699377info@ NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Caution Regarding Forward-Looking Information Certain information set forth in this news release, including, without limitation, the Company's plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law. Logo: View original content: SOURCE Innocan Pharma Corporation View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
